FDA Says Shipping Logistics Should Be Priority For Cell Therapy Products
Executive Summary
FDA says manufacturers need robust shipping programs to ensure the safety and quality of cell therapies, since there are no ready replacements and a patient’s life can be at risk if problems arise. Kite exec notes that “more than any other biologic, the supply chain of autologous cell therapies reaches really literally end-to-end.”
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
